{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-16T12:44:19.750094+00:00","company":{"ticker":"MIST","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc."},"pagination":{"limit":100,"returned":26,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"RTW Investments, LP and certain of its affiliates","detail":"asset_purchase","count":2,"first_seen":"2023-03-28T23:59:59+00:00","last_seen":"2023-03-28T23:59:59+00:00","evidence_fact_ids":[168804,168805]},{"display_name":"Piper Sandler & Co. as representative of the several underwriters","detail":"underwriting","count":1,"first_seen":"2024-03-04T23:59:59+00:00","last_seen":"2024-03-04T23:59:59+00:00","evidence_fact_ids":[69932]},{"display_name":"entities affiliated with RTW Investments","detail":"equity_purchase","count":1,"first_seen":"2023-03-27T23:59:59+00:00","last_seen":"2023-03-27T23:59:59+00:00","evidence_fact_ids":[169161]}],"lender":[{"display_name":"RTW Investments, LP and certain of its affiliates","detail":"senior_notes","count":2,"first_seen":"2023-03-31T23:59:59+00:00","last_seen":"2023-03-31T23:59:59+00:00","evidence_fact_ids":[167768,167769]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"519439f14b7e8adca618deefcdf281ca09957606","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2026-06-15T20:05:42+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Advisory Vote on Executive Compensation","proposal_type":"say_on_pay","results":[{"broker_non_votes":"48,581,161","subject":null,"votes_abstain":"702,247","votes_against":"6,990,920","votes_for":"19,665,705","votes_withheld":null}]},"claim":"Milestone Pharmaceuticals Inc. shareholders approved Advisory Vote on Executive Compensation.","evidence_excerpt":"Proposal 4. Advisory Vote on Executive Compensation Proposal 4 was a proposal for a non-binding advisory vote on the compensation of the Company’s named executive officers. The votes regarding the non-binding advisory vote were as follows: Votes For Votes Against Abstentions Broker Non-Votes 19,665,705 6,990,920 702,247 48,581,161","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-074025","anchor_url":"https://secwatch.observer/filing/0001104659-26-074025#claim-519439f14b7e8adca618deefcdf281ca09957606","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926074025/0001104659-26-074025-index.htm"},{"fact_type":"shareholder_vote","fact_key":"38a05037bd9f964b76ad78edfb225afd7e9b0c14","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2026-06-15T20:05:42+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"2019 Equity Plan Amendment","proposal_type":"equity_plan","results":[{"broker_non_votes":"48,581,158","subject":null,"votes_abstain":"2,617,059","votes_against":"5,479,043","votes_for":"19,262,773","votes_withheld":null}]},"claim":"Milestone Pharmaceuticals Inc. shareholders approved 2019 Equity Plan Amendment.","evidence_excerpt":"Proposal 3. 2019 Equity Plan Amendment Proposal 3 was a proposal to approve the 2019 EIP, as amended, to, among other things, increase the number of ordinary shares authorized for issuance by 6,800,000 shares. The votes regarding the 2019 EIP were as follows: Votes For Votes Against Abstentions Broker Non-Votes 19,262,773 5,479,043 2,617,059 48,581,158","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-074025","anchor_url":"https://secwatch.observer/filing/0001104659-26-074025#claim-38a05037bd9f964b76ad78edfb225afd7e9b0c14","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926074025/0001104659-26-074025-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f3c3278ddaf438b35a71ccf9f323c2babbc4cb70","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2026-06-15T20:05:42+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Appointment of the Auditor","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"664,912","votes_against":"249,836","votes_for":"75,025,285","votes_withheld":null}]},"claim":"Milestone Pharmaceuticals Inc. shareholders approved Appointment of the Auditor.","evidence_excerpt":"Proposal 2. Appointment of the Auditor Proposal 2 was a proposal to ratify the selection by the Company’s Audit Committee of PricewaterhouseCoopers LLP as the auditor for the Company until the close of the 2027 Annual Meeting and the authorization of the Board to fix the auditor’s remuneration. The votes regarding the ratification of the selection of the Company’s auditor were as follows: Votes For Votes Against Abstentions 75,025,285 249,836 664,912","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-074025","anchor_url":"https://secwatch.observer/filing/0001104659-26-074025#claim-f3c3278ddaf438b35a71ccf9f323c2babbc4cb70","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926074025/0001104659-26-074025-index.htm"},{"fact_type":"shareholder_vote","fact_key":"23ca5e9d1fb058b97d52722618d7bd4475e46a89","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2026-06-15T20:05:42+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"48,581,157","subject":"Joseph Oliveto","votes_abstain":null,"votes_against":null,"votes_for":"23,968,376","votes_withheld":"3,390,500"},{"broker_non_votes":"48,581,158","subject":"Stuart M. Duty","votes_abstain":null,"votes_against":null,"votes_for":"24,188,870","votes_withheld":"3,170,005"},{"broker_non_votes":"48,581,157","subject":"Seth H.Z. Fischer","votes_abstain":null,"votes_against":null,"votes_for":"24,199,513","votes_withheld":"3,159,363"},{"broker_non_votes":"48,581,157","subject":"Lisa M. Giles","votes_abstain":null,"votes_against":null,"votes_for":"24,212,031","votes_withheld":"3,146,845"},{"broker_non_votes":"48,581,159","subject":"Joseph C. Papa","votes_abstain":null,"votes_against":null,"votes_for":"23,437,235","votes_withheld":"3,921,639"},{"broker_non_votes":"48,581,158","subject":"Andrew R. Saik","votes_abstain":null,"votes_against":null,"votes_for":"24,111,218","votes_withheld":"3,247,657"},{"broker_non_votes":"48,581,157","subject":"Michael Tomsicek","votes_abstain":null,"votes_against":null,"votes_for":"24,205,006","votes_withheld":"3,153,870"},{"broker_non_votes":"48,581,158","subject":"Robert J. Wills","votes_abstain":null,"votes_against":null,"votes_for":"23,506,189","votes_withheld":"3,852,686"}]},"claim":"Milestone Pharmaceuticals Inc. shareholders approved Election of Directors.","evidence_excerpt":"Proposal 1. Election of Directors The Company’s shareholders elected the nominees below to the Company’s board of directors (the “ Board ”), each to hold office until the Company’s 2027 annual meeting of shareholders (the “ 2027 Annual Meeting ”), or until their successors are duly elected or appointed or until such directors’ earlier resignation or removal. The votes regarding the election of directors were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Joseph Oliveto 23,968,376 3,390,500 48,581,157 Stuart M. Duty 24,188,870 3,170,005 48,581,158 Seth H.Z. Fischer 24,199,513 3,159,363 48,581,157 Lisa M. Giles 24,212,031 3,146,845 48,581,157 Joseph C. Papa 23,437,235 3,921,639 48,581,159 Andrew R. Saik 24,111,218 3,247,657 48,581,158 Michael Tomsicek 24,205,006 3,153,870 48,581,157 Robert J. Wills 23,506,189 3,852,686 48,581,158","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-074025","anchor_url":"https://secwatch.observer/filing/0001104659-26-074025#claim-23ca5e9d1fb058b97d52722618d7bd4475e46a89","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926074025/0001104659-26-074025-index.htm"},{"fact_type":"earnings_release","fact_key":"923fee8d62b7f7d1168e58bf70f15a21d1b4c9e7","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2026-05-13T11:23:09+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-13","result_type":"reported_results","revenue_text":"$0.2 million"},"claim":"Milestone Pharmaceuticals Inc. reported the first quarter ended March 31, 2026 results: revenue $0.2 million.","evidence_excerpt":"into the second half of 2027, including\n expenses expected in connection with the initiation of the Phase 3 trial in AFib-RVR, as\n described above. · Product\n revenues were $0.2 million during the three months ended March 31, 2026. There was no product\n revenue during the three months ended March 31, 2025. · Research\n and development expense for the first","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-059780","anchor_url":"https://secwatch.observer/filing/0001104659-26-059780#claim-923fee8d62b7f7d1168e58bf70f15a21d1b4c9e7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926059780/0001104659-26-059780-index.htm"},{"fact_type":"earnings_release","fact_key":"182d566eaa8dd5e5524fa17b73728a43a7f141c5","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2026-03-20T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and fiscal year ended December 31, 2025","report_date":"2026-03-20","result_type":"reported_results","revenue_text":null},"claim":"Milestone Pharmaceuticals Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2025.","evidence_excerpt":"On March 20, 2026, Milestone Pharmaceuticals Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025","confidence":0.8,"filing_url":"https://secwatch.observer/filing/0001104659-26-032427","anchor_url":"https://secwatch.observer/filing/0001104659-26-032427#claim-182d566eaa8dd5e5524fa17b73728a43a7f141c5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926032427/0001104659-26-032427-index.htm"},{"fact_type":"executive_change","fact_key":"3213b77f0e","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2024-09-04T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-09-03","interim":false,"role":"member of the Board","role_category":"director","successor_name":null,"successor_named":false},"claim":"Joeseph C. Papa was elected as member of the Board at Milestone Pharmaceuticals Inc..","evidence_excerpt":"the Board of Directors (the “ Board ”) of Milestone Pharmaceuticals Inc. (the “ Company ”), upon the recommendation of the Nominating & Corporate Governance Committee of the Board, voted to elect Joeseph C. Papa as a member of the Board and as a member of the Board’s compensation committee (the “ Compensation Committee ”), effective as of September 3, 2024","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-24-096648","anchor_url":"https://secwatch.observer/filing/0001104659-24-096648#claim-3213b77f0e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465924096648/0001104659-24-096648-index.htm"},{"fact_type":"earnings_release","fact_key":"2f7168a1e4792798c836f60067eb8f41eb722d0a","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss was $10.4 million","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-13","result_type":"reported_results","revenue_text":"no revenue"},"claim":"Milestone Pharmaceuticals Inc. reported first quarter ended March 31, 2024 results: revenue no revenue, net income net loss was $10.4 million.","evidence_excerpt":"Milestone Pharmaceuticals Inc. (the \"Company\") issued a press release announcing its financial results for the first quarter ended March 31, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-060221","anchor_url":"https://secwatch.observer/filing/0001104659-24-060221#claim-2f7168a1e4792798c836f60067eb8f41eb722d0a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465924060221/0001104659-24-060221-index.htm"},{"fact_type":"earnings_release","fact_key":"f61b7aae861523304e7d92242fe687b5de584530","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2024-03-21T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and fiscal year ended December 31, 2023","report_date":"2024-03-21","result_type":"reported_results","revenue_text":null},"claim":"Milestone Pharmaceuticals Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_excerpt":"On March 21, 2024, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-036941","anchor_url":"https://secwatch.observer/filing/0001104659-24-036941#claim-f61b7aae861523304e7d92242fe687b5de584530","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465924036941/0001104659-24-036941-index.htm"},{"fact_type":"material_agreement","fact_key":"40e4e8b49673146abfc6f55b8b17df234e2fd0c7","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2024-03-04T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"Piper Sandler & Co. as representative of the several underwriters","effective_date":"2024-02-28","item_codes_triggered":["1.01"],"value_text":null},"claim":"Milestone Pharmaceuticals Inc. entered into Underwriting Agreement with Piper Sandler & Co. as representative of the several underwriters (effective 2024-02-28).","evidence_excerpt":"On February 28, 2024, Milestone Pharmaceuticals Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co. as representative of the several underwriters listed on Schedule A thereto (the “Underwriters”), related to an underwritten public offering (the “Offering”) of 16,666,667 of the Company’s common shares, without par value (the “Common Shares”), at a public offering price of $1.50 per share","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-030267","anchor_url":"https://secwatch.observer/filing/0001104659-24-030267#claim-40e4e8b49673146abfc6f55b8b17df234e2fd0c7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465924030267/0001104659-24-030267-index.htm"},{"fact_type":"earnings_release","fact_key":"80e47ede5df5333f72a34d8f9a40d1b7b9a3283a","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2023-11-13T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"third quarter ended September 30, 2023","report_date":"2023-11-13","result_type":"reported_results","revenue_text":null},"claim":"Milestone Pharmaceuticals Inc. reported financial results for third quarter ended September 30, 2023.","evidence_excerpt":"On November 13, 2023, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023, which also provided a clinical and corporate update.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-116646","anchor_url":"https://secwatch.observer/filing/0001104659-23-116646#claim-80e47ede5df5333f72a34d8f9a40d1b7b9a3283a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923116646/0001104659-23-116646-index.htm"},{"fact_type":"earnings_release","fact_key":"518f52b2db7581b03afe0db03b19cbc64ce44326","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2023-08-10T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"operating loss was $31.9 million","period_text":"the six months ended June 30, 2023","report_date":"2023-08-10","result_type":"reported_results","revenue_text":null},"claim":"Milestone Pharmaceuticals Inc. reported the six months ended June 30, 2023 results: net income operating loss was $31.9 million.","evidence_excerpt":"For the six months ended June 30, 2023, Milestone's operating loss was $31.9 million, compared to $30.9 million in the prior year period.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-089566","anchor_url":"https://secwatch.observer/filing/0001104659-23-089566#claim-518f52b2db7581b03afe0db03b19cbc64ce44326","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923089566/0001104659-23-089566-index.htm"},{"fact_type":"earnings_release","fact_key":"3b76303cb5a1b130febd2594629b0d4460ab4883","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2023-08-10T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the second quarter ended June 30, 2023","report_date":"2023-08-10","result_type":"reported_results","revenue_text":null},"claim":"Milestone Pharmaceuticals Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"On August 10, 2023, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2023, which also provided a clinical and corporate update. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-089566","anchor_url":"https://secwatch.observer/filing/0001104659-23-089566#claim-3b76303cb5a1b130febd2594629b0d4460ab4883","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923089566/0001104659-23-089566-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f039c2987b323dfab05d58debbd2d049883e469f","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2023-06-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-07","outcome":"passed","proposal_text":"Appointment of PricewaterhouseCoopers LLP as auditor","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":null,"votes_against":null,"votes_for":"23,410,435","votes_withheld":"41,638"}]},"claim":"Milestone Pharmaceuticals Inc. shareholders approved Appointment of PricewaterhouseCoopers LLP as auditor at the 2023-06-07 meeting.","evidence_excerpt":"Proposal 2.  \nAppointment of the Company’s Auditor Proposal 2 was a proposal to approve the appointment\nof PricewaterhouseCoopers LLP as the auditor for the Company to hold office until the close of the 2024 Annual Meeting of Shareholders\nand the authorization of the Board to fix the auditor's remuneration. The votes regarding the appointment of the Company’s auditor\nwere as follows: Votes For Votes Withheld 23,410,435 41,638","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-069992","anchor_url":"https://secwatch.observer/filing/0001104659-23-069992#claim-f039c2987b323dfab05d58debbd2d049883e469f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923069992/0001104659-23-069992-index.htm"},{"fact_type":"shareholder_vote","fact_key":"6c8276519c7149d009e965b8e27646e7ad28dc66","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2023-06-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-07","outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"9,626,977","subject":"Joseph Oliveto","votes_abstain":null,"votes_against":null,"votes_for":"13,813,727","votes_withheld":"11,369"},{"broker_non_votes":"9,626,977","subject":"Lisa M. Giles","votes_abstain":null,"votes_against":null,"votes_for":"13,781,817","votes_withheld":"43,279"},{"broker_non_votes":"9,626,977","subject":"Richard Pasternak","votes_abstain":null,"votes_against":null,"votes_for":"13,814,167","votes_withheld":"10,929"},{"broker_non_votes":"9,626,977","subject":"Debra K. Liebert","votes_abstain":null,"votes_against":null,"votes_for":"13,783,097","votes_withheld":"41,999"},{"broker_non_votes":"9,626,978","subject":"Michael Tomsicek","votes_abstain":null,"votes_against":null,"votes_for":"13,813,927","votes_withheld":"11,168"},{"broker_non_votes":"9,626,977","subject":"Robert J. Wills","votes_abstain":null,"votes_against":null,"votes_for":"12,507,111","votes_withheld":"1,317,985"},{"broker_non_votes":"9,626,977","subject":"Seth H.Z. Fischer","votes_abstain":null,"votes_against":null,"votes_for":"13,426,032","votes_withheld":"399,064"}]},"claim":"Milestone Pharmaceuticals Inc. shareholders approved Election of Directors at the 2023-06-07 meeting.","evidence_excerpt":"Proposal 1.  \nElection of Directors The Company’s shareholders elected the nominees\nbelow to the Company’s Board of Directors, each to hold office until the 2024 Annual Meeting of Shareholders or until their successors\nare duly elected or appointed, or until such directors' earlier resignation or removal. The votes regarding the election of directors\nwere as follows: Nominee Votes For Votes Withheld Broker Non-Votes Joseph Oliveto 13,813,727 11,369 9,626,977 Lisa M. Giles 13,781,817 43,279 9,626,977 Richard Pasternak 13,814,167 10,929 9,626,977 Debra K. Liebert 13,783,097 41,999 9,626,977 Michael Tomsicek 13,813,927 11,168 9,626,978 Robert J. Wills 12,507,111 1,317,985 9,626,977 Seth H.Z. Fischer 13,426,032 399,064 9,626,977","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-069992","anchor_url":"https://secwatch.observer/filing/0001104659-23-069992#claim-6c8276519c7149d009e965b8e27646e7ad28dc66","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923069992/0001104659-23-069992-index.htm"},{"fact_type":"earnings_release","fact_key":"9943ade5560701064095bd5901deb0724723b620","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2023-05-11T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2023","report_date":"2023-05-11","result_type":"reported_results","revenue_text":null},"claim":"Milestone Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"On May 11, 2023, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2023, which also provided a clinical and corporate update.","confidence":0.8,"filing_url":"https://secwatch.observer/filing/0001104659-23-058749","anchor_url":"https://secwatch.observer/filing/0001104659-23-058749#claim-9943ade5560701064095bd5901deb0724723b620","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923058749/0001104659-23-058749-index.htm"},{"fact_type":"debt_financing","fact_key":"ecdc2b5bd9909d6e6cc559994612ca20ab1bb6d1","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2023-03-31T23:59:59+00:00","payload":{"counterparty":"RTW Investments, LP and certain of its affiliates","effective_date":"2023-03-27","event":"incurrence","instrument_type":"other","interest_rate_text":"tiered quarterly royalty payments","item_codes_triggered":["2.03"],"maturity_text":null,"principal_text":"$75.0 million"},"claim":"Milestone Pharmaceuticals Inc. incurred debt of $75.0 million with RTW Investments, LP and certain of its affiliates at tiered quarterly royalty payments.","evidence_excerpt":"nd a Note Purchase Agreement (the “Note Purchase Agreement”) with RTW Investments, LP and certain of its affiliates (collectively,\n“RTW”). Royalty Purchase Agreement Pursuant to the Royalty Purchase Agreement, RTW","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-039764","anchor_url":"https://secwatch.observer/filing/0001104659-23-039764#claim-ecdc2b5bd9909d6e6cc559994612ca20ab1bb6d1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923039764/0001104659-23-039764-index.htm"},{"fact_type":"debt_financing","fact_key":"5179cfb0e2ecbe615cc442352f917e1f3cdc5d3e","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2023-03-31T23:59:59+00:00","payload":{"counterparty":"RTW Investments, LP and certain of its affiliates","effective_date":"2023-03-29","event":"incurrence","instrument_type":"senior_notes","interest_rate_text":"6.0%","item_codes_triggered":["2.03"],"maturity_text":"March 31, 2029","principal_text":"$50 million principal amount"},"claim":"Milestone Pharmaceuticals Inc. incurred senior notes of $50 million principal amount with RTW Investments, LP and certain of its affiliates at 6.0% maturing March 31, 2029.","evidence_excerpt":"On March 29, 2023, the Company closed the transaction contemplated by the Note Purchase Agreement and issued and sold the $50 million principal amount of 6.0% Convertible Senior Notes due 2029","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-039764","anchor_url":"https://secwatch.observer/filing/0001104659-23-039764#claim-5179cfb0e2ecbe615cc442352f917e1f3cdc5d3e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923039764/0001104659-23-039764-index.htm"},{"fact_type":"earnings_release","fact_key":"56f5b4ff970805a86085fec537ed38d5bdd0f0ec","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2023-03-29T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"fourth quarter and fiscal year ended December 31, 2022","report_date":"2023-03-29","result_type":"reported_results","revenue_text":null},"claim":"Milestone Pharmaceuticals Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2022.","evidence_excerpt":"On March 29, 2023, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022, which also provided a clinical and corporate update.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-038073","anchor_url":"https://secwatch.observer/filing/0001104659-23-038073#claim-56f5b4ff970805a86085fec537ed38d5bdd0f0ec","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923038073/0001104659-23-038073-index.htm"},{"fact_type":"material_agreement","fact_key":"8840060076cf169a5b2472ef7566ae02d68839bd","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2023-03-28T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Note Purchase Agreement","agreement_type":"notes_offering","counterparty":"RTW Investments, LP and certain of its affiliates","effective_date":"2023-03-27","item_codes_triggered":["1.01"],"value_text":"$50 million principal amount of 6.0% Convertible Senior Notes due 2029"},"claim":"Milestone Pharmaceuticals Inc. entered into Note Purchase Agreement with RTW Investments, LP and certain of its affiliates valued at $50 million principal amount of 6.0% Convertible Senior Notes due 2029 (effective 2023-03-27).","evidence_excerpt":"Pursuant to the Note Purchase Agreement, we will issue and sell $50 million principal amount of 6.0% Convertible Senior Notes due 2029 (the “2029 Convertible Notes”) to the holders, which is expected to close on March 29, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-037370","anchor_url":"https://secwatch.observer/filing/0001104659-23-037370#claim-8840060076cf169a5b2472ef7566ae02d68839bd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923037370/0001104659-23-037370-index.htm"},{"fact_type":"material_agreement","fact_key":"d5270b0addcd536be31152d5bd05f43208c68977","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2023-03-28T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Royalty Purchase Agreement","agreement_type":"asset_purchase","counterparty":"RTW Investments, LP and certain of its affiliates","effective_date":"2023-03-27","item_codes_triggered":["1.01"],"value_text":"$75.0 million"},"claim":"Milestone Pharmaceuticals Inc. entered into Royalty Purchase Agreement with RTW Investments, LP and certain of its affiliates valued at $75.0 million (effective 2023-03-27).","evidence_excerpt":"On March 27, 2023, Milestone Pharmaceuticals Inc. (the “Company”) entered into a Purchase and Sale Agreement (the “Royalty Purchase Agreement”) and a Note Purchase Agreement (the “Note Purchase Agreement”) with RTW Investments, LP and certain of its affiliates (collectively, “RTW”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-037370","anchor_url":"https://secwatch.observer/filing/0001104659-23-037370#claim-d5270b0addcd536be31152d5bd05f43208c68977","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923037370/0001104659-23-037370-index.htm"},{"fact_type":"material_agreement","fact_key":"ea9a4cdd001523c8067f2753a53d38709ce3b765","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2023-03-27T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Exchange Agreement","agreement_type":"equity_purchase","counterparty":"entities affiliated with RTW Investments","effective_date":"2023-03-22","item_codes_triggered":["1.01"],"value_text":"Exchanged 1,059,000 common shares for pre-funded warrants to purchase 1,059,000 common shares at $0."},"claim":"Milestone Pharmaceuticals Inc. entered into Exchange Agreement with entities affiliated with RTW Investments valued at Exchanged 1,059,000 common shares for pre-funded warrants to purchase 1,059,000 common shares at $0. (effective 2023-03-22).","evidence_excerpt":"On March 22, 2023, Milestone Pharmaceuticals Inc. (the “Company”) entered into an exchange agreement (the “Exchange Agreement”) with entities affiliated with RTW Investments (the “Exchanging Stockholders”), pursuant to which the Company exchanged an aggregate of 1,059,000 shares of the Company’s common shares, no par value per share (the “Common Shares”), owned by the Exchanging Stockholders for pre-funded warrants (the “Exchange Warrants”) to purchase an aggregate of 1,059,000 Common Shares, with an exercise price of $0.001 per share and no expiration date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-037189","anchor_url":"https://secwatch.observer/filing/0001104659-23-037189#claim-ea9a4cdd001523c8067f2753a53d38709ce3b765","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923037189/0001104659-23-037189-index.htm"},{"fact_type":"executive_change","fact_key":"ab6274db6e","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2023-03-27T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-03-21","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Seth H.Z. Fischer was elected as Director at Milestone Pharmaceuticals Inc..","evidence_excerpt":"voted to elect Seth H.Z. Fischer to the Board, effective as of March 21, 2023","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-23-037189","anchor_url":"https://secwatch.observer/filing/0001104659-23-037189#claim-ab6274db6e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923037189/0001104659-23-037189-index.htm"},{"fact_type":"executive_change","fact_key":"80ae252d43","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2022-12-06T23:59:59+00:00","payload":{"action":"retire","action_category":"departure","departure_tone":"retirement","effective_date":"2022-12-31","interim":false,"role":"Chief Scientific Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Francis Plat departed as Chief Scientific Officer at Milestone Pharmaceuticals Inc..","evidence_excerpt":"Mr. Oliveto, the Company’s Chief Executive Officer, announced Mr. Francis Plat’s intention to retire as Chief Scientific Officer from the Company, effective December 31, 2022.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-22-124907","anchor_url":"https://secwatch.observer/filing/0001104659-22-124907#claim-80ae252d43","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465922124907/0001104659-22-124907-index.htm"},{"fact_type":"earnings_release","fact_key":"0812d05c48fe041da01f3be8691563d9744a4917","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2022-11-10T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the third quarter ended September 30, 2022","report_date":"2022-11-10","result_type":"reported_results","revenue_text":"$1.5 million"},"claim":"Milestone Pharmaceuticals Inc. reported the third quarter ended September 30, 2022 results: revenue $1.5 million.","evidence_excerpt":"We generated revenue of $1.5 million from milestone payments under the License Agreement for the three months and nine months ended September 30, 2022 compared to no revenue in the three months ended September 30, 2021 and revenue of $15 million from upfront payments under the License Agreement during the nine months ended September 30, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-22-117099","anchor_url":"https://secwatch.observer/filing/0001104659-22-117099#claim-0812d05c48fe041da01f3be8691563d9744a4917","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465922117099/0001104659-22-117099-index.htm"},{"fact_type":"executive_change","fact_key":"f9f99e8bf0","cik":1408443,"ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2022-02-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-02-15","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"David Bharucha was appointed as Chief Medical Officer at Milestone Pharmaceuticals Inc..","evidence_excerpt":"Appointment of Chief Medical Officer On February 16, 2022, the Company announced the appointment of Dr. Bharucha as the Company’s Chief Medical Officer, effective February 15, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-22-024083","anchor_url":"https://secwatch.observer/filing/0001104659-22-024083#claim-f9f99e8bf0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465922024083/0001104659-22-024083-index.htm"}]}